Literature DB >> 8891251

Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine.

M S Reid1, M Tafti, S Nishino, R Sampathkumaran, J M Siegel, E Mignot.   

Abstract

Cataplexy in the narcoleptic canine may be modulated by systemic administration of monoaminergic compounds. In the present study, we have investigated the effects of monoaminergic drugs on cataplexy in narcoleptic canines when perfused locally via microdialysis probes in the amygdala, globus pallidus/putamen, basal forebrain, pontine reticular formation and ventral tegmental area of narcoleptic and control Doberman pinchers. Cataplexy was quantified using the Food-Elicited Cataplexy Test and analyzed by electroencephalogram, electroculogram and electromyogram. Local perfusion with the monoaminergic agonist quinpirole, 7-OH-DPAT and BHT-920, into the ventral tegmental area produced a dose-dependent increase in cataplexy without significantly reducing basal muscle tone. Perfusion with the antagonist raclopride in the same structure produced a moderate reduction in cataplexy. Local perfusion with quinpirole, 7-OH-DPAT and BHT-920 into the globus pallidus/putamen also produced an increase, while raclopride produced a decrease, in cataplexy in narcoleptic canines. In control animals, none of the above drugs produced cataplexy or muscle atonia when perfused into either the ventral tegmental area or the globus pallidus/putamen. Other monoaminergic drugs tested in these two brain areas; prazosin, yohimbine, amphetamine, SKF 38393 and SCH 23390 had no effects on cataplexy. Local perfusion with each of the above listed drugs had no effect on cataplexy in any of the other brain regions examined. These findings show that cataplexy may be regulated by D2/D3 dopaminergic receptors in the ventral tegmental area and perhaps the globus pallidus/ putamen. It is suggested that neurons in the mesolimbic dopamine system of narcoleptics are hypersensitive to dopaminergic autoreceptor agonists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891251      PMCID: PMC9050244          DOI: 10.1016/0006-8993(96)00541-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.610


  70 in total

1.  Afferent projections to the cholinergic pedunculopontine tegmental nucleus and adjacent midbrain extrapyramidal area in the albino rat. I. Retrograde tracing studies.

Authors:  T L Steininger; D B Rye; B H Wainer
Journal:  J Comp Neurol       Date:  1992-07-22       Impact factor: 3.215

2.  Effect of BHT 920 on monoaminergic neurons of the rat brain: an electrophysiological in vivo and in vitro study.

Authors:  V Seutin; J Scuvée-Moreau; I Giesbers; L Massotte; A Dresse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

3.  The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat.

Authors:  B E Jones; P Bobillier; C Pin; M Jouvet
Journal:  Brain Res       Date:  1973-08-17       Impact factor: 3.252

4.  Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy.

Authors:  S Nishino; B Fruhstorfer; J Arrigoni; C Guilleminault; W C Dement; E Mignot
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

5.  Narcolepsy: cholinergic receptor changes in an animal model.

Authors:  R E Boehme; T L Baker; I N Mefford; J D Barchas; W C Dement; R D Ciaranello
Journal:  Life Sci       Date:  1984-05-07       Impact factor: 5.037

6.  Behavioral correlates of dopaminergic unit activity in freely moving cats.

Authors:  G F Steinfels; J Heym; R E Strecker; B L Jacobs
Journal:  Brain Res       Date:  1983-01-10       Impact factor: 3.252

7.  L-tyrosine in the treatment of narcolepsy.

Authors:  J B Roufs
Journal:  Med Hypotheses       Date:  1990-12       Impact factor: 1.538

8.  Dopaminergic transmission and the sleep-wakefulness continuum in man.

Authors:  A N Nicholson; P A Pascoe
Journal:  Neuropharmacology       Date:  1990-04       Impact factor: 5.250

9.  Sleep fragmentation in canine narcolepsy.

Authors:  K I Kaitin; T S Kilduff; W C Dement
Journal:  Sleep       Date:  1986       Impact factor: 5.849

10.  The dopamine transporter: immunochemical characterization and localization in brain.

Authors:  B J Ciliax; C Heilman; L L Demchyshyn; Z B Pristupa; E Ince; S M Hersch; H B Niznik; A I Levey
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

View more
  15 in total

Review 1.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  Dopaminergic role in stimulant-induced wakefulness.

Authors:  J P Wisor; S Nishino; I Sora; G H Uhl; E Mignot; D M Edgar
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

3.  Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy.

Authors:  Kaoru Takakusaki; Kazumi Takahashi; Kazuya Saitoh; Hirofumi Harada; Toshikatsu Okumura; Yukihiko Kayama; Yoshimasa Koyama
Journal:  J Physiol       Date:  2005-08-25       Impact factor: 5.182

4.  Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy.

Authors:  Christian R Burgess; Gavin Tse; Lauren Gillis; John H Peever
Journal:  Sleep       Date:  2010-10       Impact factor: 5.849

Review 5.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

6.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

Review 7.  'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?

Authors:  K Ray Chaudhuri; Suvankar Pal; Christine Brefel-Courbon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Functional diversity of ventral midbrain dopamine and GABAergic neurons.

Authors:  Tatiana M Korotkova; Alexei A Ponomarenko; Ritchie E Brown; Helmut L Haas
Journal:  Mol Neurobiol       Date:  2004-06       Impact factor: 5.590

9.  Amygdala lesions reduce cataplexy in orexin knock-out mice.

Authors:  Christian R Burgess; Yo Oishi; Takatoshi Mochizuki; John H Peever; Thomas E Scammell
Journal:  J Neurosci       Date:  2013-06-05       Impact factor: 6.167

10.  Animal models of narcolepsy.

Authors:  Lichao Chen; Ritchie E Brown; James T McKenna; Robert W McCarley
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-08       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.